Henderson Jane
SEC-identified person · CIK 1422304 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Apogee Therapeutics, Inc. APGE | Chief Financial Officer | filed 2023 - 2026 |
| Akero Therapeutics, Inc. AKRO | Director | filed 2019 - 2025 |
| Cargo Therapeutics, Inc. CRGX | Director | filed 2024 - 2025 |
| Ophthotech Corp. OPHT | Director | filed 2018 - 2023 |
| Invivyd, Inc. IVVD | Chief Financial Officer | filed 2021 - 2022 |
| Sesen Bio, Inc. SESN | Director | filed 2014 - 2021 |
| Voyager Therapeutics, Inc. VYGR | Sr. V.P. & CFO, Corp. Dev. | filed 2017 - 2018 |
| Panacos Pharmaceuticals, INC. PANC | Chief Financial Officer, CBO | filed 2008 - 2008 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.